Great resource for drug information, reviews and discussions
MUSE (Alprostadil)
How do you rate this drug's effectiveness?
Pharmacology
Actions: Alprostadil is a synthetic prostaglandin with various pharmacological actions that include vasodilation, inhibition of platelet aggregation, inhibition of gastric secretion, stimulation of intestinal smooth muscle and stimulation of uterine smooth muscle.
Prostaglandin E 1 is a naturally occurring acidic lipid that is synthesized from fatty acid precursors by most mammalian tissues and has a variety of pharmacologic effects. Human seminal fluid is a rich source of prostaglandins, including PGE 1 and PGE 2, and the total concentration of prostaglandins in ejaculate has been estimated to be approximately 100to 200 µg/mL.
The vasodilatory effects of alprostadil on the cavernosal arteries and the trabecular smooth muscle of the corpora cavernosa result in rapid arterial inflow and expansion of the lacunar spaces within the corpora. As the expanded corporal sinusoids are compressed against the tunica albuginea, venous outflow through subtunical vessels is impeded and penile rigidity develops. This process is referred to as the corporal veno-occlusive mechanism.
Pharmacokinetics: About 80% of alprostadil administered by the MUSE system is absorbed within 10 minutes and is rapidly cleared from the systemic circulation by the lungs, leaving barely detectable systemic blood levels.
Absorption: MUSE alprostadil is designed to deliver alprostadil directly to the urethral lining for transfer via the corpus spongiosum to the corpora cavernosa. Intraurethral administration of alprostadil is preceded by urination, and the residual urine disperses the medicated pellet, permitting alprostadil to be absorbed by the urethral mucosa. The transurethral absorption of alprostadil after administration is biphasic. Initial absorption is rapid, with approximately 80% of an administered dose absorbed within 10minutes. The mean time to the maximum plasma PGE 1 concentration after a 1000µg intraurethral dose of alprostadil is approximately 16minutes.
Distribution: Following administration, alprostadil is absorbed from the urethral mucosa into the corpus spongiosum. A portion of the administered dose is transported to the corpora cavernosa through collateral vessels, while the remainder passes into the pelvic venous circulation through veins draining the corpus spongiosum. The half-life of alprostadil in humans is short, varying between 30seconds and 10minutes, depending on the body compartment in which it is measured and the physiological status of the subject. Nearly all of the alprostadil entering the central venous circulation is removed in a single pass through the lungs; thus peripheral venous plasma levels of PGE 1 are low or undetectable (<2pg/mL) after alprostadil administration. The mean maximum plasma PGE 1 concentration following intraurethral administration of the highest dose of alprostadil (1000µg) was barely detectable (11.4pg/mL). In a study of 14subjects, the plasma PGE 1 level was shown to be undetectable within 60minutes of alprostadil administration in most subjects.
Metabolism: Alprostadil is rapidly metabolized locally by enzymatic oxidation of the 15-hydroxyl group to 15-keto-PGE 1. The enzyme catalyzing this process has been isolated from many tissues in the lower genitourinary tract including the urethra, prostate, and corpus cavernosum. 15-keto-PGE 1 retains little (1to 2%) of the biological activity of PGE 1. 15-keto-PGE 1 is rapidly reduced at the C 13-C 14 position to form the most abundant metabolite in plasma, 13,14-dihydro,15-keto-PGE 1 (DHK-PGE 1), which is biologically inactive. The majority of DHK-PGE 1 is further metabolized to smaller prostaglandin remnants that are cleared primarily by the kidney and liver. Between 60 and 90% of PGE 1 has been shown to be metabolized after one pass through the pulmonary capillary beds. However, pulmonary clearance of PGE 1 can be affected by disease states such as acute respiratory distress syndrome (ARDS), with a resultant reduction in the pulmonary extraction ratio.
Excretion: After i.v. administration of tritium-labelled alprostadil in man, labelled drug disappears rapidly from the blood in the first 10minutes, and by 1hour radioactivity in the blood reaches a low level.
The metabolites of alprostadil are excreted primarily by the kidney, with approximately 90% of an administered i.v. dose excreted in the urine within 24hours of dosing. The remainder is excreted in the feces. There is no evidence of tissue retention of alprostadil or its metabolites following i.v. administration.
Pharmacokinetics in Special Populations: Pulmonary Disease: The near-complete pulmonary first-pass metabolism of PGE 1 is the primary factor influencing the systemic pharmacokinetics of alprostadil and is a reason that peripheral venous plasma levels of PGE 1 are low or undetectable (<2pg/mL) following administration. Patients with pulmonary disease, therefore, may have a reduced capacity to clear the drug. In patients with the adult respiratory distress syndrome (ARDS), pulmonary extraction of intravascularly administered alprostadil was reduced by approximately 15% compared to a control group of patients with normal respiratory function (66±3.2% vs 78±2.4%).
Geriatrics: The effects of age on the pharmacokinetics of alprostadil have not been evaluated.
Clinical Experience: The MUSE system was evaluated in 7placebo-controlled trials of various design in over 2500patients with a history of erectile dysfunction of various etiologies. These trials assessed erectile function in the clinic and sexual intercourse in outpatient settings.
Studies that established benefit demonstrated improvements in success rates for sexual intercourse compared with similarly administered placebo.
In 2 identical multicentre, double-blind, placebo-controlled, parallel-group studies, 1511monogamous and heterosexual patients were enrolled and began dose titration in the clinic with doses between 125µg and 1000µg. Sixty-six percent of patients (996) completed dose titration and achieved an erection sufficient for intercourse. Couples on active therapy were more likely to have at least one successful sexual intercourse (65% vs 19%) than were couples on placebo.
Among patients who reported successful intercourse at least once with active treatment, approximately 7of 10MUSE systems resulted in successful sexual intercourse.
Results were similar in patients with erectile dysfunction stemming from surgery or trauma, diabetes, vascular disease, or other etiologies. In administrations resulting in sexual intercourse, average erections sufficient for penetration was 16minutes on active drug. Successful therapy with alprostadil was associated with improvement in the quality of life measures of “emotional well-being” for patients and “relationship with partner” for both patients and their female partners.
Actions: Alprostadil is a synthetic prostaglandin with various pharmacological actions that include vasodilation, inhibition of platelet aggregation, inhibition of gastric secretion, stimulation of intestinal smooth muscle and stimulation of uterine smooth muscle.
Prostaglandin E 1 is a naturally occurring acidic lipid that is synthesized from fatty acid precursors by most mammalian tissues and has a variety of pharmacologic effects. Human seminal fluid is a rich source of prostaglandins, including PGE 1 and PGE 2, and the total concentration of prostaglandins in ejaculate has been estimated to be approximately 100to 200 µg/mL.
The vasodilatory effects of alprostadil on the cavernosal arteries and the trabecular smooth muscle of the corpora cavernosa result in rapid arterial inflow and expansion of the lacunar spaces within the corpora. As the expanded corporal sinusoids are compressed against the tunica albuginea, venous outflow through subtunical vessels is impeded and penile rigidity develops. This process is referred to as the corporal veno-occlusive mechanism.
Pharmacokinetics: About 80% of alprostadil administered by the MUSE system is absorbed within 10 minutes and is rapidly cleared from the systemic circulation by the lungs, leaving barely detectable systemic blood levels.
Absorption: MUSE alprostadil is designed to deliver alprostadil directly to the urethral lining for transfer via the corpus spongiosum to the corpora cavernosa. Intraurethral administration of alprostadil is preceded by urination, and the residual urine disperses the medicated pellet, permitting alprostadil to be absorbed by the urethral mucosa. The transurethral absorption of alprostadil after administration is biphasic. Initial absorption is rapid, with approximately 80% of an administered dose absorbed within 10minutes. The mean time to the maximum plasma PGE 1 concentration after a 1000µg intraurethral dose of alprostadil is approximately 16minutes.
Distribution: Following administration, alprostadil is absorbed from the urethral mucosa into the corpus spongiosum. A portion of the administered dose is transported to the corpora cavernosa through collateral vessels, while the remainder passes into the pelvic venous circulation through veins draining the corpus spongiosum. The half-life of alprostadil in humans is short, varying between 30seconds and 10minutes, depending on the body compartment in which it is measured and the physiological status of the subject. Nearly all of the alprostadil entering the central venous circulation is removed in a single pass through the lungs; thus peripheral venous plasma levels of PGE 1 are low or undetectable (<2pg/mL) after alprostadil administration. The mean maximum plasma PGE 1 concentration following intraurethral administration of the highest dose of alprostadil (1000µg) was barely detectable (11.4pg/mL). In a study of 14subjects, the plasma PGE 1 level was shown to be undetectable within 60minutes of alprostadil administration in most subjects.
Metabolism: Alprostadil is rapidly metabolized locally by enzymatic oxidation of the 15-hydroxyl group to 15-keto-PGE 1. The enzyme catalyzing this process has been isolated from many tissues in the lower genitourinary tract including the urethra, prostate, and corpus cavernosum. 15-keto-PGE 1 retains little (1to 2%) of the biological activity of PGE 1. 15-keto-PGE 1 is rapidly reduced at the C 13-C 14 position to form the most abundant metabolite in plasma, 13,14-dihydro,15-keto-PGE 1 (DHK-PGE 1), which is biologically inactive. The majority of DHK-PGE 1 is further metabolized to smaller prostaglandin remnants that are cleared primarily by the kidney and liver. Between 60 and 90% of PGE 1 has been shown to be metabolized after one pass through the pulmonary capillary beds. However, pulmonary clearance of PGE 1 can be affected by disease states such as acute respiratory distress syndrome (ARDS), with a resultant reduction in the pulmonary extraction ratio.
Excretion: After i.v. administration of tritium-labelled alprostadil in man, labelled drug disappears rapidly from the blood in the first 10minutes, and by 1hour radioactivity in the blood reaches a low level.
The metabolites of alprostadil are excreted primarily by the kidney, with approximately 90% of an administered i.v. dose excreted in the urine within 24hours of dosing. The remainder is excreted in the feces. There is no evidence of tissue retention of alprostadil or its metabolites following i.v. administration.
Pharmacokinetics in Special Populations: Pulmonary Disease: The near-complete pulmonary first-pass metabolism of PGE 1 is the primary factor influencing the systemic pharmacokinetics of alprostadil and is a reason that peripheral venous plasma levels of PGE 1 are low or undetectable (<2pg/mL) following administration. Patients with pulmonary disease, therefore, may have a reduced capacity to clear the drug. In patients with the adult respiratory distress syndrome (ARDS), pulmonary extraction of intravascularly administered alprostadil was reduced by approximately 15% compared to a control group of patients with normal respiratory function (66±3.2% vs 78±2.4%).
Geriatrics: The effects of age on the pharmacokinetics of alprostadil have not been evaluated.
Clinical Experience: The MUSE system was evaluated in 7placebo-controlled trials of various design in over 2500patients with a history of erectile dysfunction of various etiologies. These trials assessed erectile function in the clinic and sexual intercourse in outpatient settings.
Studies that established benefit demonstrated improvements in success rates for sexual intercourse compared with similarly administered placebo.
In 2 identical multicentre, double-blind, placebo-controlled, parallel-group studies, 1511monogamous and heterosexual patients were enrolled and began dose titration in the clinic with doses between 125µg and 1000µg. Sixty-six percent of patients (996) completed dose titration and achieved an erection sufficient for intercourse. Couples on active therapy were more likely to have at least one successful sexual intercourse (65% vs 19%) than were couples on placebo.
Among patients who reported successful intercourse at least once with active treatment, approximately 7of 10MUSE systems resulted in successful sexual intercourse.
Results were similar in patients with erectile dysfunction stemming from surgery or trauma, diabetes, vascular disease, or other etiologies. In administrations resulting in sexual intercourse, average erections sufficient for penetration was 16minutes on active drug. Successful therapy with alprostadil was associated with improvement in the quality of life measures of “emotional well-being” for patients and “relationship with partner” for both patients and their female partners.
Indications
Actions: Alprostadil Is A Synthetic Prostaglandin With Various Pharmacological Actions That Include Vasodilation, Inhibition Of Platelet Aggregation, Inhibition Of Gastric Secretion, Stimulation Of Intestinal Smooth Muscle And Stimulation Of Uterine Smooth Muscle.
Prostaglandin E 1 Is A Naturally Occurring Acidic Lipid That Is Synthesized From Fatty Acid Precursors By Most Mammalian Tissues And Has A Variety Of Pharmacologic Effects. Human Seminal Fluid Is A Rich Source Of Prostaglandins, Including PGE 1 And PGE 2, And The Total Concentration Of Prostaglandins In Ejaculate Has Been Estimated To Be Approximately 100to 200 µg/mL.
The Vasodilatory Effects Of Alprostadil On The Cavernosal Arteries And The Trabecular Smooth Muscle Of The Corpora Cavernosa Result In Rapid Arterial Inflow And Expansion Of The Lacunar Spaces Within The Corpora. As The Expanded Corporal Sinusoids Are Compressed Against The Tunica Albuginea, Venous Outflow Through Subtunical Vessels Is Impeded And Penile Rigidity Develops. This Process Is Referred To As The Corporal Veno-occlusive Mechanism.
Pharmacokinetics: About 80% Of Alprostadil Administered By The MUSE System Is Absorbed Within 10 Minutes And Is Rapidly Cleared From The Systemic Circulation By The Lungs, Leaving Barely Detectable Systemic Blood Levels.
Absorption: MUSE Alprostadil Is Designed To Deliver Alprostadil Directly To The Urethral Lining For Transfer Via The Corpus Spongiosum To The Corpora Cavernosa. Intraurethral Administration Of Alprostadil Is Preceded By Urination, And The Residual Urine Disperses The Medicated Pellet, Permitting Alprostadil To Be Absorbed By The Urethral Mucosa. The Transurethral Absorption Of Alprostadil After Administration Is Biphasic. Initial Absorption Is Rapid, With Approximately 80% Of An Administered Dose Absorbed Within 10minutes. The Mean Time To The Maximum Plasma PGE 1 Concentration After A 1000µg Intraurethral Dose Of Alprostadil Is Approximately 16minutes.
Distribution: Following Administration, Alprostadil Is Absorbed From The Urethral Mucosa Into The Corpus Spongiosum. A Portion Of The Administered Dose Is Transported To The Corpora Cavernosa Through Collateral Vessels, While The Remainder Passes Into The Pelvic Venous Circulation Through Veins Draining The Corpus Spongiosum. The Half-life Of Alprostadil In Humans Is Short, Varying Between 30seconds And 10minutes, Depending On The Body Compartment In Which It Is Measured And The Physiological Status Of The Subject. Nearly All Of The Alprostadil Entering The Central Venous Circulation Is Removed In A Single Pass Through The Lungs; Thus Peripheral Venous Plasma Levels Of PGE 1 Are Low Or Undetectable (<2pg/mL) After Alprostadil Administration. The Mean Maximum Plasma PGE 1 Concentration Following Intraurethral Administration Of The Highest Dose Of Alprostadil (1000µg) Was Barely Detectable (11.4pg/mL). In A Study Of 14subjects, The Plasma PGE 1 Level Was Shown To Be Undetectable Within 60minutes Of Alprostadil Administration In Most Subjects.
Metabolism: Alprostadil Is Rapidly Metabolized Locally By Enzymatic Oxidation Of The 15-hydroxyl Group To 15-keto-PGE 1. The Enzyme Catalyzing This Process Has Been Isolated From Many Tissues In The Lower Genitourinary Tract Including The Urethra, Prostate, And Corpus Cavernosum. 15-keto-PGE 1 Retains Little (1to 2%) Of The Biological Activity Of PGE 1. 15-keto-PGE 1 Is Rapidly Reduced At The C 13-C 14 Position To Form The Most Abundant Metabolite In Plasma, 13,14-dihydro,15-keto-PGE 1 (DHK-PGE 1), Which Is Biologically Inactive. The Majority Of DHK-PGE 1 Is Further Metabolized To Smaller Prostaglandin Remnants That Are Cleared Primarily By The Kidney And Liver. Between 60 And 90% Of PGE 1 Has Been Shown To Be Metabolized After One Pass Through The Pulmonary Capillary Beds. However, Pulmonary Clearance Of PGE 1 Can Be Affected By Disease States Such As Acute Respiratory Distress Syndrome (ARDS), With A Resultant Reduction In The Pulmonary Extraction Ratio.
Excretion: After I.v. Administration Of Tritium-labelled Alprostadil In Man, Labelled Drug Disappears Rapidly From The Blood In The First 10minutes, And By 1hour Radioactivity In The Blood Reaches A Low Level.
The Metabolites Of Alprostadil Are Excreted Primarily By The Kidney, With Approximately 90% Of An Administered I.v. Dose Excreted In The Urine Within 24hours Of Dosing. The Remainder Is Excreted In The Feces. There Is No Evidence Of Tissue Retention Of Alprostadil Or Its Metabolites Following I.v. Administration.
Pharmacokinetics In Special Populations: Pulmonary Disease: The Near-complete Pulmonary First-pass Metabolism Of PGE 1 Is The Primary Factor Influencing The Systemic Pharmacokinetics Of Alprostadil And Is A Reason That Peripheral Venous Plasma Levels Of PGE 1 Are Low Or Undetectable (<2pg/mL) Following Administration. Patients With Pulmonary Disease, Therefore, May Have A Reduced Capacity To Clear The Drug. In Patients With The Adult Respiratory Distress Syndrome (ARDS), Pulmonary Extraction Of Intravascularly Administered Alprostadil Was Reduced By Approximately 15% Compared To A Control Group Of Patients With Normal Respiratory Function (66±3.2% Vs 78±2.4%).
Geriatrics: The Effects Of Age On The Pharmacokinetics Of Alprostadil Have Not Been Evaluated.
Clinical Experience: The MUSE System Was Evaluated In 7placebo-controlled Trials Of Various Design In Over 2500patients With A History Of Erectile Dysfunction Of Various Etiologies. These Trials Assessed Erectile Function In The Clinic And Sexual Intercourse In Outpatient Settings.
Studies That Established Benefit Demonstrated Improvements In Success Rates For Sexual Intercourse Compared With Similarly Administered Placebo.
In 2 Identical Multicentre, Double-blind, Placebo-controlled, Parallel-group Studies, 1511monogamous And Heterosexual Patients Were Enrolled And Began Dose Titration In The Clinic With Doses Between 125µg And 1000µg. Sixty-six Percent Of Patients (996) Completed Dose Titration And Achieved An Erection Sufficient For Intercourse. Couples On Active Therapy Were More Likely To Have At Least One Successful Sexual Intercourse (65% Vs 19%) Than Were Couples On Placebo.
Among Patients Who Reported Successful Intercourse At Least Once With Active Treatment, Approximately 7of 10MUSE Systems Resulted In Successful Sexual Intercourse.
Results Were Similar In Patients With Erectile Dysfunction Stemming From Surgery Or Trauma, Diabetes, Vascular Disease, Or Other Etiologies. In Administrations Resulting In Sexual Intercourse, Average Erections Sufficient For Penetration Was 16minutes On Active Drug. Successful Therapy With Alprostadil Was Associated With Improvement In The Quality Of Life Measures Of “emotional Well-being” For Patients And “relationship With Partner” For Both Patients And Their Female Partners.
Actions: Alprostadil Is A Synthetic Prostaglandin With Various Pharmacological Actions That Include Vasodilation, Inhibition Of Platelet Aggregation, Inhibition Of Gastric Secretion, Stimulation Of Intestinal Smooth Muscle And Stimulation Of Uterine Smooth Muscle.
Prostaglandin E 1 Is A Naturally Occurring Acidic Lipid That Is Synthesized From Fatty Acid Precursors By Most Mammalian Tissues And Has A Variety Of Pharmacologic Effects. Human Seminal Fluid Is A Rich Source Of Prostaglandins, Including PGE 1 And PGE 2, And The Total Concentration Of Prostaglandins In Ejaculate Has Been Estimated To Be Approximately 100to 200 µg/mL.
The Vasodilatory Effects Of Alprostadil On The Cavernosal Arteries And The Trabecular Smooth Muscle Of The Corpora Cavernosa Result In Rapid Arterial Inflow And Expansion Of The Lacunar Spaces Within The Corpora. As The Expanded Corporal Sinusoids Are Compressed Against The Tunica Albuginea, Venous Outflow Through Subtunical Vessels Is Impeded And Penile Rigidity Develops. This Process Is Referred To As The Corporal Veno-occlusive Mechanism.
Pharmacokinetics: About 80% Of Alprostadil Administered By The MUSE System Is Absorbed Within 10 Minutes And Is Rapidly Cleared From The Systemic Circulation By The Lungs, Leaving Barely Detectable Systemic Blood Levels.
Absorption: MUSE Alprostadil Is Designed To Deliver Alprostadil Directly To The Urethral Lining For Transfer Via The Corpus Spongiosum To The Corpora Cavernosa. Intraurethral Administration Of Alprostadil Is Preceded By Urination, And The Residual Urine Disperses The Medicated Pellet, Permitting Alprostadil To Be Absorbed By The Urethral Mucosa. The Transurethral Absorption Of Alprostadil After Administration Is Biphasic. Initial Absorption Is Rapid, With Approximately 80% Of An Administered Dose Absorbed Within 10minutes. The Mean Time To The Maximum Plasma PGE 1 Concentration After A 1000µg Intraurethral Dose Of Alprostadil Is Approximately 16minutes.
Distribution: Following Administration, Alprostadil Is Absorbed From The Urethral Mucosa Into The Corpus Spongiosum. A Portion Of The Administered Dose Is Transported To The Corpora Cavernosa Through Collateral Vessels, While The Remainder Passes Into The Pelvic Venous Circulation Through Veins Draining The Corpus Spongiosum. The Half-life Of Alprostadil In Humans Is Short, Varying Between 30seconds And 10minutes, Depending On The Body Compartment In Which It Is Measured And The Physiological Status Of The Subject. Nearly All Of The Alprostadil Entering The Central Venous Circulation Is Removed In A Single Pass Through The Lungs; Thus Peripheral Venous Plasma Levels Of PGE 1 Are Low Or Undetectable (<2pg/mL) After Alprostadil Administration. The Mean Maximum Plasma PGE 1 Concentration Following Intraurethral Administration Of The Highest Dose Of Alprostadil (1000µg) Was Barely Detectable (11.4pg/mL). In A Study Of 14subjects, The Plasma PGE 1 Level Was Shown To Be Undetectable Within 60minutes Of Alprostadil Administration In Most Subjects.
Metabolism: Alprostadil Is Rapidly Metabolized Locally By Enzymatic Oxidation Of The 15-hydroxyl Group To 15-keto-PGE 1. The Enzyme Catalyzing This Process Has Been Isolated From Many Tissues In The Lower Genitourinary Tract Including The Urethra, Prostate, And Corpus Cavernosum. 15-keto-PGE 1 Retains Little (1to 2%) Of The Biological Activity Of PGE 1. 15-keto-PGE 1 Is Rapidly Reduced At The C 13-C 14 Position To Form The Most Abundant Metabolite In Plasma, 13,14-dihydro,15-keto-PGE 1 (DHK-PGE 1), Which Is Biologically Inactive. The Majority Of DHK-PGE 1 Is Further Metabolized To Smaller Prostaglandin Remnants That Are Cleared Primarily By The Kidney And Liver. Between 60 And 90% Of PGE 1 Has Been Shown To Be Metabolized After One Pass Through The Pulmonary Capillary Beds. However, Pulmonary Clearance Of PGE 1 Can Be Affected By Disease States Such As Acute Respiratory Distress Syndrome (ARDS), With A Resultant Reduction In The Pulmonary Extraction Ratio.
Excretion: After I.v. Administration Of Tritium-labelled Alprostadil In Man, Labelled Drug Disappears Rapidly From The Blood In The First 10minutes, And By 1hour Radioactivity In The Blood Reaches A Low Level.
The Metabolites Of Alprostadil Are Excreted Primarily By The Kidney, With Approximately 90% Of An Administered I.v. Dose Excreted In The Urine Within 24hours Of Dosing. The Remainder Is Excreted In The Feces. There Is No Evidence Of Tissue Retention Of Alprostadil Or Its Metabolites Following I.v. Administration.
Pharmacokinetics In Special Populations: Pulmonary Disease: The Near-complete Pulmonary First-pass Metabolism Of PGE 1 Is The Primary Factor Influencing The Systemic Pharmacokinetics Of Alprostadil And Is A Reason That Peripheral Venous Plasma Levels Of PGE 1 Are Low Or Undetectable (<2pg/mL) Following Administration. Patients With Pulmonary Disease, Therefore, May Have A Reduced Capacity To Clear The Drug. In Patients With The Adult Respiratory Distress Syndrome (ARDS), Pulmonary Extraction Of Intravascularly Administered Alprostadil Was Reduced By Approximately 15% Compared To A Control Group Of Patients With Normal Respiratory Function (66±3.2% Vs 78±2.4%).
Geriatrics: The Effects Of Age On The Pharmacokinetics Of Alprostadil Have Not Been Evaluated.
Clinical Experience: The MUSE System Was Evaluated In 7placebo-controlled Trials Of Various Design In Over 2500patients With A History Of Erectile Dysfunction Of Various Etiologies. These Trials Assessed Erectile Function In The Clinic And Sexual Intercourse In Outpatient Settings.
Studies That Established Benefit Demonstrated Improvements In Success Rates For Sexual Intercourse Compared With Similarly Administered Placebo.
In 2 Identical Multicentre, Double-blind, Placebo-controlled, Parallel-group Studies, 1511monogamous And Heterosexual Patients Were Enrolled And Began Dose Titration In The Clinic With Doses Between 125µg And 1000µg. Sixty-six Percent Of Patients (996) Completed Dose Titration And Achieved An Erection Sufficient For Intercourse. Couples On Active Therapy Were More Likely To Have At Least One Successful Sexual Intercourse (65% Vs 19%) Than Were Couples On Placebo.
Among Patients Who Reported Successful Intercourse At Least Once With Active Treatment, Approximately 7of 10MUSE Systems Resulted In Successful Sexual Intercourse.
Results Were Similar In Patients With Erectile Dysfunction Stemming From Surgery Or Trauma, Diabetes, Vascular Disease, Or Other Etiologies. In Administrations Resulting In Sexual Intercourse, Average Erections Sufficient For Penetration Was 16minutes On Active Drug. Successful Therapy With Alprostadil Was Associated With Improvement In The Quality Of Life Measures Of “emotional Well-being” For Patients And “relationship With Partner” For Both Patients And Their Female Partners.
Contraindications
Known hypersensitivity to alprostadil. Abnormal penile anatomy: Alprostadil is contraindicated in patients with urethral stricture, balanitis (inflammation/infection of the glans of the penis), severe hypospadias and curvatures, and in patients with acute or chronic urethritis. Sickle cell anemia or trait, thrombocythemia, polycythemia, multiple myeloma: alprostadil is contraindicated in patients who are prone to venous thrombosis or who have a hyperviscosity syndrome and are therefore at increased risk of priapism (rigid erection lasting 6or more hours). Alprostadil should not be used in men for whom sexual activity is inadvisable (see Precautions, General). Alprostadil should not be used for sexual intercourse with a pregnant woman unless the couple uses a condom barrier.
Known hypersensitivity to alprostadil. Abnormal penile anatomy: Alprostadil is contraindicated in patients with urethral stricture, balanitis (inflammation/infection of the glans of the penis), severe hypospadias and curvatures, and in patients with acute or chronic urethritis. Sickle cell anemia or trait, thrombocythemia, polycythemia, multiple myeloma: alprostadil is contraindicated in patients who are prone to venous thrombosis or who have a hyperviscosity syndrome and are therefore at increased risk of priapism (rigid erection lasting 6or more hours). Alprostadil should not be used in men for whom sexual activity is inadvisable (see Precautions, General). Alprostadil should not be used for sexual intercourse with a pregnant woman unless the couple uses a condom barrier.
Safety Information / Warning
Warnings: Because of the potential for symptomatic hypotension and syncope, which occurred in 3% and 0.4%, respectively, of patients during in-clinic dosing, alprostadil titration should be carried out under medical supervision.
Occupational Hazards: There exists a possibility of syncope or fainting occurring within 1hour of postadministration of alprostadil. Patients should be cautioned to avoid activities, such as driving or hazardous tasks, where injury could result if hypotension or syncope were to occur after the administration of alprostadil.
Warnings: Because of the potential for symptomatic hypotension and syncope, which occurred in 3% and 0.4%, respectively, of patients during in-clinic dosing, alprostadil titration should be carried out under medical supervision.
Occupational Hazards: There exists a possibility of syncope or fainting occurring within 1hour of postadministration of alprostadil. Patients should be cautioned to avoid activities, such as driving or hazardous tasks, where injury could result if hypotension or syncope were to occur after the administration of alprostadil.
Precautions
General: A complete medical history and physical examination should be undertaken to exclude reversible causes of erectile dysfunction prior to the initiation of alprostadil therapy. In addition, underlying disorders that might preclude the use of the MUSE system (see Contraindications) should be sought.
Cardiovascular Effects: During in-clinic dosing, patients should be monitored for symptoms of hypotension, and the lowest effective dose of alprostadil should be prescribed.
Hematologic Effects: Patients administering alprostadil improperly may be at risk of urethral abrasion resulting in minor bleeding or spotting. Patients on anticoagulant therapy or with bleeding disorders may be at higher risk of bleeding. Patients on anticoagulant therapy have been safely treated with alprostadil; however, the risk/benefit ratio in these patients should be considered prior to prescribing alprostadil.
Resumption of Sexual Activity: Sexual intercourse is considered a vigorous physical activity, and it increases heart rate as well as cardiac work. Physicians may want to examine the cardiac fitness of patients prior to treating erectile dysfunction.
Priapism and Prolonged Erection: In clinical trials of alprostadil, priapism (rigid erection lasting ³6hours) and prolonged erection (rigid erection lasting 4 and <6hours) were reported infrequently (<0.1% and 0.3% of patients, respectively). Nevertheless, these events are a potential risk of pharmacologic therapy and can cause penile injury. Physicians should lower the dose or consider discontinuing treatment with alprostadil in any patient who develops priapism or prolonged erection.
Drug Interactions : Because there are low or undetectable (<2pg/mL) amounts of alprostadil found in the peripheral venous circulation following administration, systemic drug-drug interactions with alprostadil are unlikely. The presence of medications in the circulation that attenuate erectile function, however, may influence the response to alprostadil.
Although formal studies have not been conducted, the concomitant use of alprostadil and antihypertension medications may increase the risk of hypotension. It is therefore advised that caution be used in the administration of alprostadil to individuals on anti-hypertensive medications. In addition, the presence of medication in the circulation that attenuate erectile function may influence the response to alprostadil.
Drug-device Interactions : Use of the MUSE system in patients with penile implants has not been studied.
Sexual Preference: There is no experience in homosexual men and no experience with other than vaginal intercourse.
Lactation and Children: Alprostadil is not indicated for use in women or children.
General: A complete medical history and physical examination should be undertaken to exclude reversible causes of erectile dysfunction prior to the initiation of alprostadil therapy. In addition, underlying disorders that might preclude the use of the MUSE system (see Contraindications) should be sought.
Cardiovascular Effects: During in-clinic dosing, patients should be monitored for symptoms of hypotension, and the lowest effective dose of alprostadil should be prescribed.
Hematologic Effects: Patients administering alprostadil improperly may be at risk of urethral abrasion resulting in minor bleeding or spotting. Patients on anticoagulant therapy or with bleeding disorders may be at higher risk of bleeding. Patients on anticoagulant therapy have been safely treated with alprostadil; however, the risk/benefit ratio in these patients should be considered prior to prescribing alprostadil.
Resumption of Sexual Activity: Sexual intercourse is considered a vigorous physical activity, and it increases heart rate as well as cardiac work. Physicians may want to examine the cardiac fitness of patients prior to treating erectile dysfunction.
Priapism and Prolonged Erection: In clinical trials of alprostadil, priapism (rigid erection lasting ³6hours) and prolonged erection (rigid erection lasting 4 and <6hours) were reported infrequently (<0.1% and 0.3% of patients, respectively). Nevertheless, these events are a potential risk of pharmacologic therapy and can cause penile injury. Physicians should lower the dose or consider discontinuing treatment with alprostadil in any patient who develops priapism or prolonged erection.
Drug Interactions : Because there are low or undetectable (<2pg/mL) amounts of alprostadil found in the peripheral venous circulation following administration, systemic drug-drug interactions with alprostadil are unlikely. The presence of medications in the circulation that attenuate erectile function, however, may influence the response to alprostadil.
Although formal studies have not been conducted, the concomitant use of alprostadil and antihypertension medications may increase the risk of hypotension. It is therefore advised that caution be used in the administration of alprostadil to individuals on anti-hypertensive medications. In addition, the presence of medication in the circulation that attenuate erectile function may influence the response to alprostadil.
Drug-device Interactions : Use of the MUSE system in patients with penile implants has not been studied.
Sexual Preference: There is no experience in homosexual men and no experience with other than vaginal intercourse.
Lactation and Children: Alprostadil is not indicated for use in women or children.
Side Effects / Adverse Effects
In-Clinic Titration: In the 2largest double-blind, parallel, placebo-controlled trials, 1511patients received alprostadil at least 1time in the clinic setting. The most frequently reported drug-related side effects during in-clinic titration included pain in the penis (36%), urethra (13%), or testes (5%). These discomforts were most commonly reported as mild and transient, but about 7% of patients withdrew at this stage because of adverse events. Urethral bleeding/spotting and other minor abrasions to the urethra were reported in approximately 3% of patients.
Symptomatic lowering of blood pressure (hypotension) occurred in 3% of patients. Dizziness was reported in 4% of patients. Syncope (fainting) was reported by 0.4% of patients.
Home Treatment: 996 patients (66% of those who began titration) were studied during the home treatment portion of 2Phase III placebo-controlled studies. Fewer than 2% of patients discontinued from these studies primarily because of adverse events.
Other drug-related side effects observed during in-clinic titration and home treatment include swelling of leg veins, leg pain, perineal pain, and rapid pulse, each occurring in <2% of patients.
Female Partner Adverse Events: The most common drug-related adverse event reported by female partners during placebo-controlled clinical studies was vaginal burning/itching, reported by 5.8% of partners of patients on active vs 0.8% of partners of patients on placebo. It is unknown whether this adverse event experienced by female partners was a result of the medication or a result of resuming sexual intercourse, which occurred much more frequently in partners of patients on active medication.
In-Clinic Titration: In the 2largest double-blind, parallel, placebo-controlled trials, 1511patients received alprostadil at least 1time in the clinic setting. The most frequently reported drug-related side effects during in-clinic titration included pain in the penis (36%), urethra (13%), or testes (5%). These discomforts were most commonly reported as mild and transient, but about 7% of patients withdrew at this stage because of adverse events. Urethral bleeding/spotting and other minor abrasions to the urethra were reported in approximately 3% of patients.
Symptomatic lowering of blood pressure (hypotension) occurred in 3% of patients. Dizziness was reported in 4% of patients. Syncope (fainting) was reported by 0.4% of patients.
Home Treatment: 996 patients (66% of those who began titration) were studied during the home treatment portion of 2Phase III placebo-controlled studies. Fewer than 2% of patients discontinued from these studies primarily because of adverse events.
Other drug-related side effects observed during in-clinic titration and home treatment include swelling of leg veins, leg pain, perineal pain, and rapid pulse, each occurring in <2% of patients.
Female Partner Adverse Events: The most common drug-related adverse event reported by female partners during placebo-controlled clinical studies was vaginal burning/itching, reported by 5.8% of partners of patients on active vs 0.8% of partners of patients on placebo. It is unknown whether this adverse event experienced by female partners was a result of the medication or a result of resuming sexual intercourse, which occurred much more frequently in partners of patients on active medication.
Overdose
ymptoms and Treatment: Overdosage has not been reported with alprostadil. Overdosage with alprostadil may result in hypotension, persistent penile pain, and possibly priapism (rigid erection lasting ³6 hours). Priapism can result in permanent worsening of erectile function. Patients suspected of overdosage who develop these symptoms should be kept under medical supervision until systemic or local symptoms have resolved and/or until penile detumescence has occurred. Symptomatic treatment of any systemic symptoms would be appropriate.
Patients should be instructed to report any erections persisting for more than 4 hours to a physician. The treatment of priapism/prolonged erection should be according to established medical practice. Physicians may refer to 2suggested protocols for detumescence presented below.
Detumescence Protocols: 1.Aspirate 40to 60mL from either right or left corpora using vacutainer and holder as for drawing blood. Patient will often detumesce while aspirating. Apply ice for 20minutes postaspiration if erection remains.
If 1. is unsuccessful then,
2.Have patient in supine position. Dilute 10mg phenylephrine into 20 mL water for injection (0.05%). With an insulin syringe, inject 0.1 to 0.2 mL (50 to 100µg) into the corpora every 2to 5minutes, until detumescence occurs. The occasional patient may experience very transient bradycardia and hypertension when given phenylephrine injections, therefore monitor patient's blood pressure and pulse every 10 minutes. Patients at risk include those with cardiac arrhythmias and diabetics. Refer to the prescribing information for phenylephrine before use. Do not give to patients on MAO inhibitors. When phenylephrine is used within the first 12hours of erection, the majority of patients will respond.
3.If the above measures fail to detumesce the patient, a urologist should be consulted as soon as possible, especially if the erection has been present for many hours. If priapism is not treated immediately, penile tissue damage and/or permanent loss of potency may result.
ymptoms and Treatment: Overdosage has not been reported with alprostadil. Overdosage with alprostadil may result in hypotension, persistent penile pain, and possibly priapism (rigid erection lasting ³6 hours). Priapism can result in permanent worsening of erectile function. Patients suspected of overdosage who develop these symptoms should be kept under medical supervision until systemic or local symptoms have resolved and/or until penile detumescence has occurred. Symptomatic treatment of any systemic symptoms would be appropriate.
Patients should be instructed to report any erections persisting for more than 4 hours to a physician. The treatment of priapism/prolonged erection should be according to established medical practice. Physicians may refer to 2suggested protocols for detumescence presented below.
Detumescence Protocols: 1.Aspirate 40to 60mL from either right or left corpora using vacutainer and holder as for drawing blood. Patient will often detumesce while aspirating. Apply ice for 20minutes postaspiration if erection remains.
If 1. is unsuccessful then,
2.Have patient in supine position. Dilute 10mg phenylephrine into 20 mL water for injection (0.05%). With an insulin syringe, inject 0.1 to 0.2 mL (50 to 100µg) into the corpora every 2to 5minutes, until detumescence occurs. The occasional patient may experience very transient bradycardia and hypertension when given phenylephrine injections, therefore monitor patient's blood pressure and pulse every 10 minutes. Patients at risk include those with cardiac arrhythmias and diabetics. Refer to the prescribing information for phenylephrine before use. Do not give to patients on MAO inhibitors. When phenylephrine is used within the first 12hours of erection, the majority of patients will respond.
3.If the above measures fail to detumesce the patient, a urologist should be consulted as soon as possible, especially if the erection has been present for many hours. If priapism is not treated immediately, penile tissue damage and/or permanent loss of potency may result.
Recommended Dosage
MUSE alprostadil is a transurethral delivery system available in 3dosage strengths: 250, 500 and 1000µg. Alprostadil should be administered as needed to achieve an erection. The onset of effect is within 5to 10minutes after administration. The duration of effect is approximately 30to 60minutes. However, the actual duration will vary from patient to patient. Each patient should be instructed by a medical professional on proper technique for administering alprostadil prior to self-administration. The maximum frequency of use is no more than 2systems per 24-hour period.
Initiation of Therapy: Dose titration should be undertaken under the supervision of a physician to test a patient's responsiveness to alprostadil, to demonstrate proper administration technique (see Blue Section--Information for the Patient), and to monitor for evidence of hypotension. Patients should be individually titrated to the lowest dose that is sufficient for sexual intercourse. The 250µg dose of alprostadil is recommended for initial dosing. If necessary, the dose should be increased (or decreased) on separate occasions in a stepwise manner until the patient achieves an erection that is sufficient for sexual intercourse.
Home Treatment Regimen: Alprostadil should be used as needed to achieve an erection. The maximum frequency of use is 2administrations per 24-hour period. Each MUSE system is for single-use only and should be properly discarded after use.
Information for the Patient: See Blue Section--Information for the Patient “MUSE”.
MUSE alprostadil is a transurethral delivery system available in 3dosage strengths: 250, 500 and 1000µg. Alprostadil should be administered as needed to achieve an erection. The onset of effect is within 5to 10minutes after administration. The duration of effect is approximately 30to 60minutes. However, the actual duration will vary from patient to patient. Each patient should be instructed by a medical professional on proper technique for administering alprostadil prior to self-administration. The maximum frequency of use is no more than 2systems per 24-hour period.
Initiation of Therapy: Dose titration should be undertaken under the supervision of a physician to test a patient's responsiveness to alprostadil, to demonstrate proper administration technique (see Blue Section--Information for the Patient), and to monitor for evidence of hypotension. Patients should be individually titrated to the lowest dose that is sufficient for sexual intercourse. The 250µg dose of alprostadil is recommended for initial dosing. If necessary, the dose should be increased (or decreased) on separate occasions in a stepwise manner until the patient achieves an erection that is sufficient for sexual intercourse.
Home Treatment Regimen: Alprostadil should be used as needed to achieve an erection. The maximum frequency of use is 2administrations per 24-hour period. Each MUSE system is for single-use only and should be properly discarded after use.
Information for the Patient: See Blue Section--Information for the Patient “MUSE”.
Supplied / Packaging
Transurethral delivery system contains: alprostadil 250, 500 or 1000µg. Nonmedicinal ingredients: polyethylene glycol USP. Store unopened foil pouches in a refrigerator at 2to 8°C. Do not expose to temperatures above 30°C. May be kept by the patient at room temperature (below 30°C) for up to 14days prior to use.
Transurethral delivery system contains: alprostadil 250, 500 or 1000µg. Nonmedicinal ingredients: polyethylene glycol USP. Store unopened foil pouches in a refrigerator at 2to 8°C. Do not expose to temperatures above 30°C. May be kept by the patient at room temperature (below 30°C) for up to 14days prior to use.
